



Invitation to SenzaGen's 2020 half year report conference call on Aug 20 at 9.30 CEST

Lund, August 13, 2020

SenzaGen is pleased to invite press and investors to a conference call on Thursday August 20 at 9.30 CEST where CEO Axel Sjöblad comments SenzaGen's 2020 half year results.

The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for the conference

To participate in the conference call, use the dial-in numbers below.

SE: +46850558351

FR: +33170750737

DE: +4969222239167

CH: +41225675632

NE: +31107129162

UK: +443333009269

Weblink

<https://tv.streamfabriken.com/senzagen-q2-2020>

Contacts

Axel Sjöblad, CEO, SenzaGen AB

Email: axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708-20 29 44



About us

About GARD

GARD™ consists of a group of tests for analysing a chemical's capacity to trigger an allergic reaction in humans. The tests target companies looking to optimize their testing strategy and increase the accuracy of their test results while avoiding animal testing. With precision and reliability, GARD improves the quality of customers' decision-making and contributes to increased product safety while reducing the number of animal tests. SenzaGen is the only company at this time that can provide an *in vitro* test to determine whether a chemical causes respiratory allergies. The Company's product portfolio consists of tests for skin and respiratory allergies: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

About SenzaGen AB (publ)

SenzaGen's technology enables the replacement of animal testing with genetic testing in test tubes to determine the allergenicity of the chemicals we come in contact with in our everyday lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The Company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct and through partners. SenzaGen has its headquarters in Lund, Sweden, and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company's Certified Adviser.

Attachments

[Invitation to SenzaGen's 2020 half year report conference call on Aug 20 at 9.30 CEST](#)